Nash

or Nashe (năsh), Thomas 1567-1601.

English writer noted for his witty, often invective literary criticism and for The Unfortunate Traveller (1594), a picaresque adventure narrative.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

Nash

(næʃ)

1. (Biography) John. 1752–1835, English town planner and architect. He designed Regent's Park, Regent Street, and the Marble Arch in London

2. (Biography) Ogden. 1902–71, US humorous poet

3. (Biography) Paul. 1889–1946, English painter, noted esp as a war artist in both World Wars and for his landscapes

4. (Biography) Richard, known as Beau Nash. 1674–1762, English dandy

5. (Biography) See (Thomas) Nashe

6. (Biography) Sir Walter. 1882–1968, New Zealand Labour statesman, born in England: prime minister of New Zealand (1957–60)

Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

Nash

(næʃ)

n.

1. Ogden, 1902–71, U.S. poet.

2. Also, Nashe. Thomas ( “Pasquil” ), 1567–1601, English playwright and satirist.

Nash

An automobile named after Charles W. Nash, made by the Nash Motor Company of Kenosha, WI from 1917 until 1954, and by the American Motor Company from 1954 through 1957.

ThesaurusAntonymsRelated WordsSynonymsLegend:

Noun

Nash - United States writer noted for his droll epigrams (1902-1971)

Ogden Nash

Mentioned in

References in periodicals archive

The global nonalcoholic steatohepatitis treatment market size was valued at US$ 1,119.9 million in 2017 (based on existing approved therapies anti-diabetics, vitamins, dietary supplements, and others) and is expected to witness a CAGR of 42.7% over the forecast period (2018 - 2026).

Nonalcoholic Steatohepatitis Treatment Market is expected to Foresee Tremendous Growth by 2026 / Insights by Drug, Distribution and Regional Forecast 2026

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30(6):1356-62.

BIOCHEMICAL PROFILE AND VARIOUS TREATMENT MODALITIES OF PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)

The partnership has generated several early drug discovery targets shown to inhibit biological processes associated with inflammation and fibrosis that can lead to nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer.

HemoShear, Takeda

But it seems like hepatitis C--related liver disease is being replaced quickly by liver disease from nonalcoholic steatohepatitis. This transition between hepatitis C as the most important cause of liver disease and liver mortality to NASH or obesity-related NASH is becoming more rapid than I expected."

U.S. death rates from chronic liver disease continue to rise

Treatment with TDZs has been demonstrated to improve hypoadiponectinemia, hepatic steatosis, lobular inflammation, and insulin resistance in patients with nonalcoholic steatohepatitis [46].

Rosiglitazone Elicits an Adiponectin-Mediated Insulin-Sensitizing Action at the Adipose Tissue-Liver Axis in Otsuka Long-Evans Tokushima Fatty Rats

[4-7] NALFD includes nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver, liver cirrhosis and hepatocellular carcinoma.

Predictors of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with type-2 diabetes mellitus

A multimodal research process has provided clues to the role of angiogenesis in the etiology of nonalcoholic fatty liver disease (NAFLD) and its more serious cousin, nonalcoholic steatohepatitis (NASH).

Angiogenesis plays role in NASH and NAFLD

(2) The spectrum of NAFLD ranges from simple steatosis to nonalcoholic steatohepatitis (NASFI) to cirrhosis.

Non-alcoholic fatty liver disease: What's in our arsenal?

A meta-analysis of trials examining the effects of vitamin E supplementation in individuals with nonalcoholic steatohepatitis (NASH) affirmed a benefit for the vitamin in association with several facets of the disease.

Protective effect of vitamin E against nonalcoholic steatohepatitis

Three quarters of HIV-positive adults with high liver enzymes and without viral hepatitis had undetected liver disease, (1) including more than half with nonalcoholic steatohepatitis (NASH *) (2) and fibrosis *, which can lead to permanent liver disease.

High liver enzymes signal serious disease in HIV-positives without viral hepatitis